Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Ichnos’ CEO Dr Cyril Konto highlights promising early data presented at ASH for the firm’s trispecific antibody in multiple myeloma versus teclistamab and alnuctamab. He also outlines why the US-based spin out of Glenmark isn’t considering the special purpose acquisition company alternative to the conventional IPO.
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.